Stocks of companies in mainland China generally have lagged those in the U.S., Taiwan, and Hong Kong in the first half of 2021, partly influenced by China’s tighter monetary policy, as well as rising regulatory and geopolitical risk. After a recent pullback, Fidelity’s Ivan Xie says select growth stocks in the country are now approaching attractive prices.
“Our team has found reasonable stock valuations and improved risk-reward profiles for long-duration growth names, and we’re excited about recent opportunities,” says Xie, co-manager of Fidelity® China Region Fund (FHKCX).
Xie and co-managers Stephen Lieu and Peifang Sun seek high-quality growth stocks at reasonable valuations as well as cyclical stocks at cheap valuations. They say they are finding some “great” opportunities in the former category as of midyear.
China’s economy is increasingly known for its new-economy sectors, says Xie, who cites Meituan (MPNGF) as a domestically oriented company that is taking advantage of mega-trends in the country.
Meituan is a dominant local-services provider that hooks up locals with everything from food delivery to spa services and hotel bookings, Xie says. The stock trended generally lower from mid-February through the end of May, due to losses related to expanding its community group-buying services. Yet Xie believes the company could succeed longer term, and accumulated shares on price weakness.
Also in recent months, the co-managers added a position in Zai Lab (ZLAB), a biotechnology company that’s working on treatments for autoimmune ailments, infectious diseases, and cancer. Xie says the company’s management team continues to execute well by signing attractive licensing deals for drugs it can bring to market in China, while also developing in-house drugs.
Lastly, Xie and team raised the fund’s stake in Pinduoduo (PDD), which they consider one of the leading e-commerce players in China, with dominant positions in lower-tier cities in the country. The company takes part in the community group-buying trend in China, which got its start amid the pandemic and remains popular, according to Xie.
“We’re finding many innovative, fast-growing e-commerce, tech, and biotech stories in China with solid business models and access to huge local markets that are trading at surprisingly fair prices,” Xie says.
Fidelity® China Region Fund held securities mentioned in this article as of its most recent holdings disclosure. For specific fund information, including holdings, please click on the fund trading symbol above.
As with all your investments through Fidelity, you must make your own determination whether an investment in any particular security or securities is consistent with your investment objectives, risk tolerance, financial situation, and evaluation of the security. Fidelity is not recommending or endorsing this investment by making it available to its customers.
Past performance is no guarantee of future results.
Views expressed are as of the date indicated, based on the information available at that time, and may change based on market or other conditions. Unless otherwise noted, the opinions provided are those of the speaker or author and not necessarily those of Fidelity Investments or its affiliates. Fidelity does not assume any duty to update any of the information.
Fidelity Brokerage Services LLC, Member NYSE, SIPC, 900 Salem Street, Smithfield, RI 02917